Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.

Abstract

BACKGROUND:

This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF).

METHODS:

We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization.

RESULTS:

In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29).

CONCLUSIONS:

In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425).

• Authors: Milton Packer, Wilson Colucci, Lloyd Fisher, Barry M Massie, John R Teerlink, James Young, Robert J Padley, Roopal Thakkar, Leticia Delgado-Herrera, Jeffrey Salon, Chris Garratt, Bidan Huang, Toni Sarapohja, REVIVE Heart Failure Study Group
• Journal: JACC. Heart failure (JACC Heart Fail) Vol. 1 Issue 2 Pg. 103-11 (Apr 2013) ISSN: 2213-1787 [Electronic] United States
• PMID: 24621834 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Cardiotonic Agents
• Hydrazones
• Pyridazines
• Simendan

Topics

• Cardiotonic Agents (therapeutic use)
• Double-Blind Method
• Female
• Heart Failure (drug therapy)
• Humans
• Hydrazones (therapeutic use)
• Male
• Middle Aged
• Prospective Studies
• Pyridazines (therapeutic use)
• Simendan